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Objective: To assess the efficacy of nepafenac 0.1% ophthalmic suspension in improving the 
clinical outcomes following cataract surgery (CS) in patients with nonproliferative diabetic 
retinopathy.
Methods: In two similar multicenter, randomized studies, patients received either nepafenac 
0.1% or vehicle, instilled three times daily starting a day prior to surgery and continuing for 
90 days postoperatively. A post hoc analysis of these two studies was conducted to assess 1) the 
likelihood for development of postoperative macular edema (ME), based on the percentage of 
patients who developed ME (30% increase from preoperative baseline in central subfield 
macular thickness) within 90 days following CS and 2) best-corrected visual acuity (BCVA) 
endpoints, including the percentage of patients with a BCVA improvement of 15 letters from 
preoperative baseline to Day 14 and maintained through Day 90. Results for individual studies 
and their pooled estimates (only visual acuity endpoints) are reported. Primary inference was 
based on odds ratio (OR).
Results: This post hoc analysis included 411 patients (nepafenac 0.1%: 205; vehicle: 206). 
The incidence of postoperative ME within 90 days of CS was notably lower in the nepafenac-
treated patients than in vehicle-treated patients (study 1: 3.2% vs 16.7%; OR =0.2, 95% 
confidence interval [CI] =0.1, 0.5, P=0.001; study 2: 5.0% vs 17.5%; OR =0.2, 95% CI =0.1, 
0.8, P=0.018). A higher percentage of nepafenac-treated patients than vehicle-treated patients 
gained 15 letters from preoperative baseline to Day 14, which was maintained through Day 
90 (study 1: 38.4% vs 21.4%; OR =2.4, 95% CI =1.4, 4.2, P=0.003; study 2: 35.0% vs 25.0%; 
OR =1.6, 95% CI =0.8, 3.2, P=0.172; pooled: 37.1% vs 22.8%; OR =2.0, 95% CI =1.3, 3.1, 
P=0.001). The odds of 5-letter and 10-letter loss in BCVA from postoperative Day 7 were 
higher in vehicle-treated than in nepafenac-treated patients.
Conclusion: These results support the clinical benefit of prophylactic use of nepafenac 0.1% 
for reducing the risk of postoperative ME and for improvement in BCVA outcomes following 
CS in patients with nonproliferative diabetic retinopathy.
Keywords: cataract surgery, nonproliferative diabetic retinopathy, nepafenac 0.1%, postopera-
tive macular edema, visual outcomes
Introduction
Postoperative macular edema (ME) following cataract surgery is an important cause 
for suboptimal visual outcomes, particularly in high-risk patients such as those with 
diabetes.1–8 A retrospective database study of 81,984 consecutive phacoemulsification 
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cataract operations found the incidence of postoperative ME 
to be four times higher in patients with diabetes and the rela-
tive risk of postoperative ME to increase in proportion with 
the severity of diabetic retinopathy (DR).9
The prostaglandin-mediated inflammatory response trig-
gered as a result of trauma during cataract surgery is consid-
ered to be an underlying cause for the development of ME.4 
The effectiveness of topical anti-inflammatory agents, such 
as corticosteroids and nonsteroidal anti-inflammatory drugs 
(NSAIDs), that are commonly used for the management of 
postoperative ocular inflammation and pain, has also been 
studied for the prevention of postoperative ME.1,2,10,11
Nepafenac (Alcon Research Ltd, Fort Worth, TX, USA), 
a topical ocular NSAID, is available as an ophthalmic suspen-
sion in concentrations of 0.1% and 0.3%.12,13 Unlike other 
NSAIDs, nepafenac is a prodrug that is deaminated to its 
active metabolite (amfenac) in the ocular tissues.14,15 Both 
nepafenac and amfenac are potent inhibitors of cyclooxy-
genase isoforms, COX-1 and COX-2, and distribute rapidly 
in both the anterior and posterior segments of the eye.14–16 
The high bioavailability of nepafenac in the posterior 
segment serves as a reservoir for hydrolysis to amfenac and 
accounts for nepafenac’s prolonged activity in the ocular 
tissues.14–16
The nepafenac 0.1% and 0.3% ophthalmic suspensions 
are the only NSAIDs approved in Europe for the reduction 
in the risk of postoperative ME associated with cataract sur-
gery in patients with diabetes, with a recommended use for 
up to 60 days postoperatively.7 An extended treatment with 
nepafenac ophthalmic suspension 0.1% for 90 days after cata-
ract surgery was shown to result in statistically significant and 
clinically relevant reduction in the risk of postoperative ME, 
and also a better maintenance of visual acuity (VA) in patients 
with nonproliferative diabetic retinopathy (NPDR).17,18
To gain additional understanding of the efficacy of 
nepafenac 0.1% in improving clinical outcomes following 
cataract surgery in patients with diabetes and NPDR, a post 
hoc analysis was conducted for data from the two individual 
nepafenac 0.1% studies as well as the pooled data from the 
two studies.
Methods
study design
This post hoc analysis included data from two, multicenter, 
randomized, double-masked, controlled, parallel-group trials. 
One was a phase II study conducted between 2008 and 2010 
at study centers in the USA (NCT00782717; study 1) and the 
other was a phase III study conducted between 2009 and 2010 
at study centers in the USA, Europe, Middle East, and Asia 
Pacific (NCT00939276; study 2). The detailed study designs 
of the two studies have been published previously.17,18 Both 
the studies were conducted in accordance with the Good 
Clinical Practice and the Declaration of Helsinki. Each study 
protocol was reviewed and approved by an Independent 
Ethics Committee or an Institutional Review Board for each 
participating center. All patients provided written informed 
consent before entering the respective study.
The two trials were similar in design (Figure 1). Briefly, 
patients were administered either nepafenac 0.1% or vehicle, 
instilled three times daily in the study eye, on the day prior to 
cataract surgery, on the day of surgery, and for 90 days there-
after. An additional one drop of the study medication was 
administered 30–120 minutes prior to surgery. In all patients, 
regardless of the assigned study drug, a corticosteroid 
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Figure 1 study design.
Abbreviation: nPDr, nonproliferative diabetic retinopathy.
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(study 1: OMNIPRED™, prednisolone acetate ophthalmic 
suspension; study 2: TOBRADEX® tobramycin and dex-
amethasone ophthalmic suspension) was instilled into the 
study eye four times daily for 2 weeks postsurgery. There 
were six postsurgical visits (days 1, 7, 14, 30, 60, and 90) in 
both studies. The only differences between the two studies 
were the eligibility requirements in central subfield macular 
thickness (CSMT) and the method for optical coherence 
tomography (OCT). In the phase II study, macular thickness 
was measured using time domain OCT and the ME cut-off 
was CSMT 250 µm, while in the phase III study, spectral 
domain OCT (SD-OCT) was used and the ME cut-off was 
CSMT 320 µm.17,18
In both studies, eligible patients were aged 18 years 
and had a cataract that required extraction by phacoemulsi-
fication with planned implantation of the posterior chamber 
intraocular lens, and had diabetes (Type 1 or Type 2) and 
were diagnosed with NPDR (mild, moderate, or severe) as 
defined by the International Clinical Diabetic Retinopathy 
Disease Severity Scale.17,18 At least 50% of the randomized 
patients in each treatment arm had to have moderate or 
severe NPDR. Patients with pre-existing ME in the study 
eye were excluded.
Post hoc analyses assessments
The efficacy and safety data from the two individual 
studies have been published previously.17,18 In this post 
hoc analysis, the endpoints assessed in the individual 
studies were the following: the percentage of patients who 
developed ME (defined as 30% increase from preopera-
tive baseline in CSMT) within 90 days following cataract 
surgery; the percentage of patients with a best-corrected 
visual acuity (BCVA) improvement of 15 letters from 
preoperative baseline to Day 14 and maintained through 
Day 90; the percentage of patients with a BCVA improve-
ment of 15 letters from preoperative baseline to Day 90 
and Day 60; the percentage with BCVA loss of 5 letters 
and 10 letters from Day 7 to any visit; and mean change 
from baseline in BCVA. The post hoc analysis of pooled 
data from the two studies only included the VA endpoints, 
since different OCT methods were used in the two studies 
for assessment of ME. There were no safety assessments in 
this post hoc analysis.
statistical analyses
The post hoc efficacy analysis was conducted on the full 
analysis set which consisted of all patients who completed the 
implant surgery and had at least one on-therapy postsurgical 
visit. For the pooled analysis, the full analysis sets of the 
respective studies were pooled for each treatment arm.
A logistic regression model was employed that included 
treatment and retinopathy severity terms to compare odds of 
event outcomes. The primary inference for ME and BCVA 
endpoints was based on the odds ratio (OR). The estimated 
OR, associated 95% confidence intervals (CIs), and P-values 
were calculated. The percentage of patients with BCVA 
improvement of 15 letters from preoperative baseline 
to Day 14 and maintained through Day 90 was based on a 
binary variable (positive outcome; negative outcome) which 
was derived using the change from preoperative baseline in 
BCVA at Day 14, Day 30, Day 60, and Day 90. A positive 
outcome required that BCVA improvement from preopera-
tive baseline be 15 letters at all four visits (days 14, 30, 
60, and 90). Any response short of BCVA improvement 
of 15 letters at all four visits was considered a negative 
outcome. A patient with BCVA data missing at one or more 
than one visit was considered as a negative outcome. For 
the mean change from baseline, the estimated difference in 
means by visit and the associated 95% CIs were provided. 
Descriptive statistics were used to summarize baseline and 
demographic characteristics, and data were presented by 
treatment group.
Results
The baseline and demographic characteristics of all patients 
included in the analysis are shown in Table 1. The pooled 
population included 411 patients (nepafenac 0.1% group: 
205; vehicle: 206). Overall, the two treatment groups were 
well balanced. The mean age of patients was 67 years, ~46% 
were males, and 80% were white. In both treatment 
groups, 50% patients had moderate NPDR and 38% 
patients had mild NPDR (Table 1).
Me endpoint
As previously reported, in both studies, a significantly 
lower percentage of patients in nepafenac 0.1%-treated 
group developed ME relative to those in the vehicle group 
(study 1: 3.2% vs 16.7%, P=0.001; study 2: 5.0% vs 17.5%, 
P=0.012).17,18 In this post hoc analysis, the odds of developing 
postoperative ME within 90 days of cataract surgery were 
observed to be notably lower in nepafenac 0.1%-treated 
group than in the vehicle-treated group in the two studies 
(study 1: OR =0.2, 95% CI =0.1, 0.5, P=0.001; study 2: 
OR =0.2; 95% CI =0.1, 0.8, P=0.018). No pooled analysis 
was performed for this endpoint due to differences in the 
OCT methodology used in the two studies.
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BCVa endpoints
As shown in Figure 2, a higher percentage of nepafenac 0.1%-
treated patients had a BCVA improvement of 15 letters 
from preoperative baseline to Day 14 and maintained through 
Day 90, compared with vehicle (study 1: 38.4% vs 21.4%, 
P=0.003; study 2: 35.0% vs 25.0%, P=0.172). The analysis 
of pooled data from the two studies also showed that treat-
ment with nepafenac 0.1% was associated with a higher 
odds of achieving a BCVA improvement of 15 letters 
from preoperative baseline to Day 14 maintained through 
Day 90, as compared to vehicle (37.1% vs 22.8%; OR =2.0, 
95% CI =1.3, 3.1; P=0.001).
As shown in Figure 3, while the percentage of patients 
with an improvement in VA of 15 letters from preoperative 
baseline to Day 90 was higher in the nepafenac 0.1% group 
than in the vehicle group, the difference between the groups 
was notable in study 1 (55.2% vs 34.9%, P=0.001), but not 
in study 2 (47.5% vs 35%, P=0.111). However, in the pooled 
estimate, treatment with nepafenac 0.1% was associated with 
an increased odds of improvement in VA of 15 letters from 
preoperative baseline to Day 90, compared with vehicle 
(52.2% vs 35%; OR =2.0, 95% CI =1.4, 3.0; P,0.001).
Similarly, the percentage of patients with an improve-
ment in VA of 15 letters from preoperative baseline 
Table 1 Demographic and baseline characteristics of patients in each treatment group by individual study and pooled data (Fas)
 Study 1 Study 2 Pooled
Nepafenac  
0.1%, n=126
Vehicle,  
n=125
Nepafenac 
0.1%, n=80
Vehicle,  
n=80
Nepafenac  
0.1%, n=205
Vehicle,  
n=206
Mean age, years (±sD) 66.6 (9.3) 66.4 (9.7) 68.1 (8.6) 69.4 (7.7) 67.2 (9.0) 67.5 (9.0)
Male, n (%) 42 (33.6) 51 (40.5) 51 (63.8) 44 (55.0) 93 (45.4) 95 (46.1)
Race, n (%)
White 97 (77.6) 108 (85.7) 69 (86.3) 71 (88.8) 166 (81.0) 179 (86.9)
Black/african–american 21 (16.8) 13 (10.3) 1 (1.3) 0 (0) 22 (10.7) 13 (6.3)
american indian/alaska native 0 (0) 1 (0.8) – – 0 (0) 1 (0.5)
asian 7 (5.6) 1 (0.8) 6 (7.5) 5 (6.3) 13 (6.3) 6 (2.9)
Native Hawaiian/other Pacific Islander 0 (0) 0 (0) 2 (2.5) 2 (2.5) 2 (1.0) 2 (1.0)
Other 0 (0) 3 (2.4) 2 (2.5) 2 (2.5) 2 (1.0) 5 (2.4)
CsMT, mean (±sD) 197.9 (26.6) 203.6 (24.8) 268.8 (29.0) 276.8 (23.2) 225.6 (44.2) 232.0 (43.1)
Mean BCVa (±sD) 68.2 (9.3) 66.7 (14.1) 62.5 (14.5) 64.3 (14.1) 65.9 (11.9) 65.8 (14.1)
Retinopathy severity, n (%)
Mild 19 (15.2) 26 (20.6) 58 (72.5) 57 (71.3) 77 (37.6) 83 (40.3)
Moderate 89 (71.2) 86 (68.3) 21 (26.3) 22 (27.5) 110 (53.7) 108 (52.4)
severe 17 (13.6) 14 (11.1) 1 (1.3) 1 (1.3) 18 (8.8) 15 (7.3)
Abbreviations: BCVA, best-corrected visual acuity; CSMT, central subfield macular thickness; FAS, full analysis set; SD, standard deviation.
Figure 2 Percentage of patients with BCVa improvement of 15 letters from preoperative baseline to Day 14 and maintained through Day 90 in each treatment group by 
individual study and pooled data (Fas).
Notes: P-value (study 1: 0.003; study 2: 0.172; pooled: 0.001); *P,0.05.
Abbreviations: BCVA, best-corrected visual acuity; CI, confidence interval; FAS, full analysis set; OR, odds ratio; SE, standard error.
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to Day 60 was higher in the nepafenac 0.1% group than 
in vehicle, the difference between treatment groups was 
notable in study 1 (P=0.046), but not in study 2 (P=0.272; 
Figure 4). In the pooled estimate, treatment with nepafenac 
0.1% was associated with an increased odds of improvement 
in VA of 15 letters from preoperative baseline to Day 60 
(OR =1.6; 95% CI =1.1, 2.3; P=0.025; Figure 4).
The percentage of patients with a loss in VA of 5 letters 
or 10 letters from Day 7 to any visit was more in the 
vehicle than in the nepafenac 0.1% group. For both these 
BCVA endpoints, the odds for postoperative loss in VA were 
notably lower with nepafenac 0.1% compared with vehicle 
in study 1 and in the analysis of pooled data from the two 
studies (P,0.001), but not in study 2 (P0.05; Table 2).
The mean changes in BCVA for patients in nepafenac 
0.1%- and vehicle-treated groups at all postoperative visits 
are shown in Table 3. The mean change from baseline in 
BCVA at all postoperative visits up to Day 90 was greater in 
the nepafenac 0.1% group than in the vehicle group, although 
the difference between the two treatment groups was notable 
only at Day 60 (in study 1 and in the analysis of pooled data 
from the two studies, but not in study 2; Table 3).
Figure 3 Percentage of patients with BCVa improvement of 15 letters from preoperative baseline and maintained through Day 90 in each treatment group by individual 
study and pooled data (Fas).
Notes: P-value (study 1: 0.001; study 2: 0.111; pooled: ,0.001); *P,0.05.
Abbreviations: BCVA, best-corrected visual acuity; CI, confidence interval; FAS, full analysis set; OR, odds ratio; SE, standard error.
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Figure 4 Percentage of patients with BCVa improvement of 15 letters from preoperative baseline and maintained through Day 60 in each treatment group by individual 
study and pooled data (Fas).
Notes: P-value (study 1: 0.046; study 2: 0.272; pooled: 0.025); *P,0.05.
Abbreviations: BCVA, best-corrected visual acuity; CI, confidence interval; FAS, full analysis set; OR, odds ratio; SE, standard error.
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Discussion
The results of this post hoc analyses corroborated the find-
ings from the two individual studies, that prophylactic 
treatment with nepafenac 0.1%, initiated 1 day prior to and 
continued for 90 days after the cataract surgery, reduces 
the risk of postoperative ME in patients with diabetes and 
NPDR, compared to vehicle. Treatment with nepafenac 
0.1% was found to lower the odds of postoperative ME by 
80% in these patients, compared with vehicle. This finding 
is consistent with the primary analysis of data in the two 
studies that had shown the incidence of postoperative ME 
to be three- to five fold lower in the nepafenac 0.1% group 
than in the vehicle group.17,18 Recently, the nepafenac 0.3% 
ophthalmic suspension administered once daily for 90 days 
postoperatively has also been shown to reduce the risk of 
postoperative ME in patients with NPDR.19
Table 2 summary of BCVa outcomes in each treatment group by individual study and pooled data (Fas)
Endpoint Nepafenac 
0.1%, n (%)
Vehicle, 
n (%)
OR (95% CI) P-value
study 1 n=125 n=126
BCVa improvement of 15 letters from preoperative baseline to Day 14 
and maintained through Day 90
48 (38.4) 27 (21.4) 2.4 (1.4, 4.2) 0.003*
BCVa improvement of 15 letters from preoperative baseline to Day 90 69 (55.2) 44 (34.9) 2.4 (1.4, 3.9) 0.001*
BCVa improvement of 15 letters from preoperative baseline to Day 60 65 (52.0) 50 (39.7) 1.7 (1.0, 2.8) 0.046*
BCVa 5-letter loss from Day 7 to any visit 19 (15.2) 54 (42.9) 0.2 (0.1, 0.4) ,0.001*
BCVa 10-letter loss from Day 7 to any visit 9 (7.2) 36 (28.6) 0.2 (0.1, 0.4) ,0.001*
study 2 n=80 n=80
BCVa improvement of 15 letters from preoperative baseline to Day 14 
and maintained through Day 90
28 (35.0) 20 (25.0) 1.6 (0.8, 3.2) 0.172
BCVa improvement of 15 letters from preoperative baseline to Day 90 38 (47.5) 28 (35.0) 1.7 (0.9, 3.2) 0.111
BCVa improvement of 15 letters from preoperative baseline to Day 60 42 (52.5) 35 (43.8) 1.4 (0.8, 2.6) 0.272
BCVa 5-letter loss from Day 7 to any visit 36 (45.0) 43 (53.8) 0.7 (0.4, 1.3) 0.274
BCVa 10-letter loss from Day 7 to any visit 30 (37.5) 37 (46.3) 0.7 (0.4, 1.3) 0.269
Pooled n=205 n=206
BCVa improvement of 15 letters from preoperative baseline to Day 14 
and maintained through Day 90
76 (37.1) 47 (22.8) 2.0 (1.3, 3.1) 0.001*
BCVa improvement of 15 letters from preoperative baseline to Day 90 107 (52.2) 72 (35.0) 2.0 (1.4, 3.0) ,0.001*
BCVa improvement of 15 letters from preoperative baseline to Day 60 107 (52.2) 85 (41.3) 1.6 (1.1, 2.3) 0.025*
BCVa 5-letter loss from Day 7 to any visit 55 (26.8) 97 (47.1) 0.4 (0.3, 0.6) ,0.001*
BCVa 10-letter loss from Day 7 to any visit 39 (19.0) 73 (35.4) 0.4 (0.3, 0.7) ,0.001*
Note: *P,0.05.
Abbreviations: BCVA, best-corrected visual acuity; CI, confidence interval; FAS, full analysis set; OR, odds ratio.
Table 3 Mean BCVa at baseline and at each postoperative visit in each treatment group by individual study and pooled data (Fas)
BCVA Study 1 Study 2 Pooled data
Nepafenac  
0.1%, (n=125)
Vehicle,  
(n=126)
P-value Nepafenac  
0.1%, (n=80)
Vehicle,  
(n=80)
P-value Nepafenac  
0.1%, (n=205)
Vehicle,  
(n=206)
P-value
Baseline BCVa
Mean (sD) 68.2 (9.3) 66.7 (14.1) 62.5 (14.5) 64.3 (14.1) 65.9 (11.9) 65.8 (14.1)
Day 7 (n) 125 121 80 80 205 201
Mean (sD) 81.3 (7.5) 80.4 (7.3) 0.412 77.5 (12.0) 79.3 (8.0) 0.325 79.8 (9.7) 80.0 (7.6) 0.856
Day 14 (n) 125 123 78 80 203 203
Mean (sD) 82.7 (7.4) 80.1 (7.6) 0.004* 78.6 (11.1) 79.0 (7.7) 0.825 81.1 (9.2) 79.6 (7.7) 0.073
Day 30 (n) 123 115 74 73 197 188
Mean (sD) 82.4 (9.2) 81.3 (6.7) 0.196 79.3 (13.5) 76.2 (18.2) 0.233 81.3 (11.1) 79.3 (12.7) 0.078
Day 60 (n) 117 111 68 66 185 177
Mean (sD) 83.9 (5.9) 82.0 (6.2) 0.055 80.7 (13.1) 79.0 (12.3) 0.253 82.7 (9.3) 80.8 (9.0) 0.047*
Day 90 (n) 119 103 66 54 185 157
Mean (sD) 84.2 (6.3) 82.7 (5.8) 0.092 76.3 (21.7) 81.3 (7.7) 0.208 81.4 (14.3) 82.2 (6.5) 0.784
Note: *P,0.05.
Abbreviations: BCVa, best-corrected visual acuity; Fas, full analysis set; sD, standard deviation.
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here suggest that the reduction in risk of postoperative ME 
observed in the two studies is primarily due to nepafenac 
0.1% treatment. Although all patients had received addi-
tional corticosteroid treatment, the ME and VA findings 
were in favor of the group receiving nepafenac 0.1% than 
vehicle at all postoperative time points in both the studies. 
This is supported by another study that directly compared 
nepafenac with a topical corticosteroid in low-risk patients; 
after cataract extraction, nepafenac was found to be more 
effective in preventing cystoid ME and leading to more rapid 
visual recovery.20
A limitation of the results presented in this study was 
that all analyses were post hoc. Thus, claims to statistical 
significance were not made. Furthermore, study 2 was 
terminated early, with only 67% of the planned sample 
size enrolled due to patient recruitment difficulties. The 
reduced sample size in study 2 could have contributed to 
the relatively weaker results for VA endpoints, compared 
to study 1 results. However, VA outcomes in study 2 were 
numerically in favor of nepafenac 0.1% suspension than 
vehicle and, thus, directionally consistent with study 1. 
Though study 1 and study 2 had similar inclusion criteria, 
they differed in the OCT technique used: time domain OCT 
vs SD-OCT. Due to greater sensitivity of SD-OCT to detect 
retinal anatomy, a high percentage of screened patients, 
such as even those with small cystoid abnormalities/more 
severe retinopathy, were excluded, which severely limited 
the enrollment in study 2.
Safety was not assessed as part of this post hoc analysis. 
However, the safety profile of nepafenac has been established 
across several studies. The adverse events reported in the two 
nepafenac 0.1% studies included in this post hoc analyses 
were consistent with those reported in previous nepafenac 
studies.20,21,31 Overall, no new safety signals were identified 
with the extended use of nepafenac 0.1% for up to 90 days 
following cataract surgery in either study.17,18
Conclusion
These results support the clinical benefit with the prophylactic 
use of nepafenac suspension 0.1%, beginning preoperatively, 
in reducing the risk of postoperative ME and for early and 
sustained improvement in BCVA outcomes following 
an uneventful cataract surgery in patients with diabetes 
and NPDR.
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One of the quality measures of cataract surgery is the 
percentage of patients achieving a VA of 20/40 or better 
(distance or near) within 90 days following an uneventful 
cataract extraction.22 While good visual prognosis is reported 
in diabetic patients after cataract surgery, the percentage of 
patients, especially those with DR, achieving better than 
20/40 vision is lower than that reported for nondiabetic 
patients.23–25 Suboptimal visual function severely impacts 
the quality of life; therefore, early restoration of vision 
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result in exacerbation of ME or retinopathy progression.27–31 
Therefore, DR patients require careful management of post-
operative inflammation to ensure stable vision, and thus, a 
preventive approach would help in reducing the risk of visual 
impairment due to ME.
Contrasting reports exist regarding the beneficial role 
of NSAIDs in reducing the risk of postoperative ME after 
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in a systematic review of randomized clinical trials that in 
patients with diabetes, a combination of topical NSAIDs and 
corticosteroids significantly reduced the odds of developing 
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additive effect of the two anti-inflammatory drugs.2 How-
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